BOOST3 is a randomized controlled trial to compare the effectiveness of goal-directed critical care based upon monitoring of brain tissue oxygen and intracranial pressure versus monitoring of intracranial pressure alone in patients with severe traumatic brain injury.
ICECAP is a randomized controlled trial to determine if identifying an optimal duration of cooling can improve outcomes in patients following resuscitation from cardiac arrest.
BRAVO is a randomized controlled trial to compare the effectiveness of a new oral drug for snakebite envenomation.
ACUPUNCTURE is a pragmatic two-stage adaptive randomized clinical trial of 2 types of acupuncture vs usual care for acute musculoskeletal pain.
REVVED UP was a cross-sectional survey conducted from December 10, 2020, to March 7, 2021, at 15 safety net US Emergency Departments to learn about COVID-19 vaccine hesitancy and potential sites of COVID-19 vaccine receipt.
We enrolled many patients into different studies of High-Sensitivity Troponin tests, which led to more than one assay being approved by the FDA for clinical use.
COVID Studies
Regeneron was an adaptive, phase 1/2/3, randomized, double-blinded, placebo-controlled master protocol to evaluate the efficacy, safety, and tolerability of CASIRIVIMAB AND IMDEVIMAB combination therapy in ambulatory patients with COVID-19. It ultimately showed this drug was effective for reducing the rate of hospitalization and death compared to placebo.
We participated in the study which led to FDA approval of the Abbott Binax test- lateral flow immunochromatographic point of care test for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen.
C3PO was a randomized, multicenter, single-blind trial of convalescent plasma with a high titer of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) versus placebo in patients who were being treated in an emergency department for COVID-19.
CLOVERS was an unblinded superiority trial in which patients with hypotension from septic shock were treated with either a restrictive fluid strategy (prioritizing vasopressors and lower intravenous fluid volumes) or a liberal fluid strategy (prioritizing higher volumes of intravenous fluids before vasopressor use) for a 24-hour period.